A spray that helps men last six times longer in bed has been developed by British doctors, "said the Sun. He said the tests showed that dew increased sex to nearly four minutes. involving 300 men with premature ejaculation used the spray or placebo five minutes before intercourse.Men who were used the spray on verlengde their intercourse from 0.6 minute to 3.8 minutes, while the placebo group increased to 1.1 min.
The men in this study had a premature ejaculation for life and the spray would not necessarily have the same effect on men without the condition that they simply want sex to last longer. The drug is also not "Viagra spray" because it contains different drugs and, unlike Viagra, is not used to treat erectile dysfunction. Additional randomized controlled trials are needed to determine whether PSD502 aerosol has advantages over other treatments, such as behavioral or other drug therapies.
Where did the story come from?
Dr. W Wallace Dinsmore of the Royal Victoria Hospital Belfast in Michael G Wyllie of Plethora Solutions Ltd (the company that makes the PSD502 aerosol) were the co-authors of this study. No sources of funding are reported, one author is a director and shareholder of Plethora Solutions Ltd, while the other is a consultant and researcher of the company. The study was published in the peer-reviewed medical journal BJU International.
What kind of scientific study was this?
This was a randomized, double-blind, placebo-controlled trial. Their goal was to examine the effect of aerosol PSD502 on the duration of sexual intercourse (ejaculatory latency) in men with premature ejaculation. The PSD502 aerosol contained 7.5 mg lidocaine and 2.5 mg prilocaine, both local anesthetics.
The researchers say that although anesthetic creams are already used to successfully increase the duration of intercourse, are not specifically designed or approved for this gebruik and have more services gaps, including disorders, a long time to potentially wait and the need to use a condom.
The researchers recruited adult men over 18 from 31 centers in Europe (Czech Republic, Poland, United Kingdom and Hungary). All the men were in stable heterosexual monogamous relationships and had been diagnosed with premature ejaculation for life according to standard criteria. These defined lifetime premature ejaculation criteria as a "male sexual dysfunction characterized by ejaculation that occurs always or almost always before or about a minuut of vaginal penetration, the inability to delay spray ejaculation in all or almost all vaginal penetrations and consequences negative personalities, such as anxiety, boredom, frustration and the avoidance of sexual intimacy ".
Men who had erectile dysfunction were excluded from the study. The researchers also excluded men (or their partners) with physical or psychological problems that interfere with the study. They also banned anyone taking antidepressants from other conditions than premature ejaculation and the dose that had been changed in the last four weeks or changed during the study period. Men with alcohol or drugs, a known sensitivity to local anesthetics, those who were pregnant couples or couples who do not want to use contraception during the study, those who use certain heart medications and those who suffer specific diseases or drugs that increase Safety risks have also been excluded.
When enrolled, participants underwent a medical examination, including cardiac monitoring and completed standard questionnaires on premature ejaculation, including the rate of premature ejaculation (PEI), which includes results for ejaculatory control. and sexual satisfaction and the profile of premature ejaculation (PEP). They also rated their orgasms on a scale of five wijst ranging from "very poor" to "very good".
The 300 men who reported having ejaculated less than one minute after the onset of sexual intercourse (from penetration to ejaculation) at least two out of three over a four-week selection period were randomly assigned to a placebo aerosol or PSD502. The men were instructed to apply the spray five minutes before sexual intercourse on the penis and to write down with a stopwatch how long the sexual intercourse lasted and the side effects. Men were told not to use the vaporizer more than once every 24 hours and not to participate in an activity that would lead to ejaculation for at least 24 hours before the vaporizer would be used. Men were also not allowed to use condoms, so researchers could assess the possible effects of dew on men.
Participants continued to use aerosols for three months under double-blind conditions (neither participants nor researchers knew which aerosol they were using). Men completed the PEI and PEP questionnaires during monthly visits to the clinic. At the end of the study, they also evaluated their orgasms on the five-point scale used at the beginning of the study, judging the aerosols on a four-point scale from "bad" to "excellent" and examining their penis. The researchers compared the results of the PSD502 spray and the placebo spray.
What were the results of the study?
During the study, 18 patients withdrew from the PSD502 group (200 people) and four returned from the placebo group (100 people), mainly due to withdrawal of consent. This left 278 men with an average age of 35 years for analysis.
At the beginning of the study, men reported that sex lasted an average of 0.6 minutes. In the three-month study, both groups of men reported an increase in the average duration of sexual intercourse, but this increase was greater in the PSD502 group: 3.8 minutes in the PSD502 treatment group and 1.1 minutes in the placebo group. This represents a 6.3-fold increase with PSD502 aerosol and a 1.7-fold increase with placebo.
Men who used the shark spray reported a greater increase in their ejaculatory control and sexual satisfaction in the index of the premature ejaculation questionnaire than those who received a placebo. At the end of the study, two-thirds (66%) of men rated their PSD502 spray group as "excellent" or "good" compared to 15% in the placebo group.
There were no serious side effects, but about 3% of the men and 3% of their PSD502 partners and 1% of the men in the placebo group reported side effects that were considered treatment-related. None of the men in the placebo group reported side effects. The most common side effects in the PSD502 group were redness of the genitals, loss of erection and a burning sensation in the sexual organs of their partners.
What interpretations did the researchers draw from these results?
The researchers concluded that PSD502 delayed ejaculation and improved control of ejaculation. They say it improves sexual satisfaction in men with premature ejaculation and seems to be well tolerated. They conclude that "PSD502 appears to offer significant benefits over other therapies that are being developed for the treatment of [premature ejaculation]."
What does the NHS Knowledge Service make of this study?
This study indicates that PSD502 aerosol can delay ejaculation in men with premature ejaculation for life. The strengths include the relatively large size, the randomized design and the use of a double-blind control group and a placebo group. There are a number of things to keep in mind:
- This study included only men with a permanent diagnosis of premature ejaculation and the results may not be representative of what would happen in men who only occasionally have premature ejaculation or simply postpone ejaculation.
- Although there was a placebo control group, men could have guessed what treatment they were using because the PSD502 spray contains local anesthesia and is likely to cause a feeling of numbness. If participants have guessed which spray they have used, this may affect their assessment of sexual satisfaction and ejaculation control.
- There may have been a measurement error at the time of sexual intercourse, because this was the time that the participants had planned. This is likely to affect both groups.
Additional randomized controlled trials will be needed to determine whether PSD502 aerosol has advantages over other early ejaculation techniques, such as behavior therapy or other drug therapies.
0 Comments
Thank you for comment